+11.6%
PLTR vs MRNA
+511.3%
-499.6%
-48.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.5% | -2.2% | -2.3% | -4.4% |
| 7D | -6.4% | +5.5% | -11.9% | -6.6% |
| 30D | +10.0% | +158.7% | -148.7% | +2.5% |
| 3M | +23.0% | +182.1% | -159.1% | +13.6% |
| 6M | +13.8% | +151.8% | -138.0% | +6.0% |
| YTD | -1.9% | +393.6% | -395.5% | -13.2% |
| 1Y | +11.6% | +499.5% | -487.8% | +1.4% |
| All | +11.6% | +511.3% | -499.6% | +1.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling